Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Payables (2016 - 2025)

BioRestorative Therapies (BRTX) has disclosed Payables for 15 consecutive years, with $859898.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Payables rose 114.24% year-over-year to $859898.0, compared with a TTM value of $859898.0 through Sep 2025, up 114.24%, and an annual FY2024 reading of $483070.0, up 155.07% over the prior year.
  • Payables was $859898.0 for Q3 2025 at BioRestorative Therapies, up from $609931.0 in the prior quarter.
  • Across five years, Payables topped out at $6.0 million in Q3 2021 and bottomed at $92586.0 in Q1 2023.
  • Average Payables over 5 years is $1.1 million, with a median of $378233.0 recorded in 2022.
  • The sharpest move saw Payables soared 15940.53% in 2021, then plummeted 95.7% in 2022.
  • Year by year, Payables stood at $300827.0 in 2021, then crashed by 43.19% to $170902.0 in 2022, then rose by 10.82% to $189389.0 in 2023, then surged by 155.07% to $483070.0 in 2024, then surged by 78.01% to $859898.0 in 2025.
  • Business Quant data shows Payables for BRTX at $859898.0 in Q3 2025, $609931.0 in Q2 2025, and $599500.0 in Q1 2025.